Pharmaceutical

bit.bio defends European patent for ‘novel’ opti-ox technology

bit.bio’s method for pluripotent stem cell (PSC) programming, opti-ox, was deemed sufficiently novel and inventive.

Oct 18, 2024 - 04:00
bit.bio defends European patent for ‘novel’ opti-ox technology
bit.bio’s method for pluripotent stem cell (PSC) programming, opti-ox, was deemed sufficiently novel and inventive.
Read the original article

Tags:

Previous Article

Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to gover...

Next Article

Radiopharm and AtomVie partner on radioantibody development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EMA endorses Calliditas’ Alport syndrome drug for orphan designation

EMA endorses Calliditas’ Alport syndrome drug for orpha...

Oct 5, 2023

STAT+: Pharmalittle: PBMs are targeted in yet another congressional bill; access to new Alzheimer’s drug may not happen quickly

STAT+: Pharmalittle: PBMs are targeted in yet another c...

Jun 16, 2023

EMA approves Sanofi’s Dupixent for COPD treatment in adults

EMA approves Sanofi’s Dupixent for COPD treatment in ad...

Jul 4, 2024